HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study
Objective : To demonstrate the safety and efficacy of tibolone ( 1.25 and 2.5 mg ) in the treatment of moderate to severe vasomotor symptoms and symptoms associated with vaginal atrophy . Design : A placebo-controlled , double-blind , r and omized , multicenter study was conducted on 396 healthy postmenopausal women experiencing a minimum of 7 moderate to severe hot flashes per day ( 60 per week ) . Participants were r and omized to receive tibolone 1.25 or 2.5 mg or placebo once daily for 12 weeks . Assessment s were done at weeks 4 , 8 , and 12 . The severity and frequency of hot flashes were recorded in patient diaries on a daily basis . Results : Tibolone 2.5 mg significantly ( P < 0.001 ) reduced the average number of hot flashes compared with placebo at week 4 ( −7.82 vs −5.27 ) , week 8 ( −9.71 vs −5.86 ) , and week 12 ( −10.14 vs −5.85 ) . The difference between tibolone 1.25 mg and placebo was significant ( P < 0.001 ) at week 8 ( −7.96 ) and week 12 ( −8.32 ) . Findings for the average daily severity of hot flashes were similar , with significantly greater reductions at week 4 ( P < 0.05 ) and weeks 8 and 12 ( P < 0.001 ) for tibolone 2.5 mg versus placebo and at weeks 8 and 12 for tibolone 1.25 mg versus placebo ( P < 0.001 ) . A menopausal atrophic symptom question naire revealed that tibolone 2.5 mg significantly ( P < 0.05 ) reduced nocturia compared with placebo at weeks 4 , 8 , and 12 and urinary urgency at week 4 . Compared with placebo , both doses of tibolone also significantly ( P < 0.001 ) increased the vaginal maturation value from baseline . The overall incidence of adverse events was similar in all treatment groups . Conclusions : Tibolone is effective and well tolerated for the treatment of moderate to severe vasomotor symptoms and the effects of vaginal atrophy associated with menopause
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .